Biolab is looking for startups to co-create innovative solutions that meet 5 strategic challenges. In the 1st edition of InovaBio Open, you will have the opportunity to collaborate directly with the pharmaceutical industry by accelerating the development of disruptive technologies in various areas. Take part in this open innovation ecosystem and help turn challenges into real opportunities!
THE 5 INOVABIO OPEN 2024 CHALLENGES
We are looking for solutions that help doctors with their day-to-day demands and bring new opportunities to their field. Solutions can include the use of AI to analyze large volumes of data, identify patterns and predict outcomes, with the aim of improving decision-making and opening up new opportunities for innovative treatments.
We are looking for solutions that promote efficient integration between representatives, doctors and pharmaceutical retailers. Solutions can include tools such as digital platforms and mobile applications. The aim is to facilitate communication and provide up-to-date product information, improving the experience for all involved.
We look for solutions aimed at speeding up the development of new formulations. These can include the use of advanced software that simulates chemical reactions and physical properties and allows virtual testing, with the aim of saving time and resources and speeding up the arrival of new drugs on the market.
We seek solutions that provide new methods for evaluating new drugs, reducing the need for animal testing and making them more effective, with the aim of making the process more ethical, faster and more economical.
We are looking for solutions to increase production efficiency in the pharmaceutical industry. These solutions can include process automation, the use of cutting-edge technologies and the implementation of lean manufacturing practices. The objectives of this challenge include reducing waste, improving product quality and increasing production capacity.
INOVABIO OPEN 2024 SCHEDULE
Applications open for startups from all over Brazil
Selection of the solutions that present the most synergy with the challenges
Presentation of solutions to Biolab executives
Analysis and definition of the startups that will move on to the next phase
Deepening the challenge and elaborating the scope
Testing the solution and aligning the next steps
Biolab stands out as a pioneer of pharmaceutical innovation in Brazil, with achievements that reflect our commitment to health and scientific advancement. Find out more about our initiatives:
UNIVERSITY-COMPANY PARTNERSHIP
We have one of the largest cases of success and payment of royalties in partnership with universities.
VONAU FLASH®
Developed in partnership with the University of São Paulo (USP)*, Vonau Flash® is an innovative medicine for treating motion sickness. Its formulation allows the tablet to dissolve quickly in the mouth, which provides accelerated relief.
*INSTITUTIONAL AND NON-PROMOTIONAL/ADVERTISING MATERIAL.
PHOTOPROT®
The result of a joint project with the Federal University of Rio Grande do Sul (UFRGS), Photoprot® is a photoprotector with a sun protection factor of 99 (SPF 99) that uses nanotechnology in its formula.
SCIENTIFIC RESEARCH
Biolab also plays an active role in promoting national scientific research. Since 2009, we have sponsored the José Ribeiro do Valle Young Investigator Award, presented annually at the Brazilian Congress of Pharmacology and Experimental Therapeutics.
PARTNERSHIPS WITH STARTUPS
Collaboration with startups is key to driving continuous innovation and bringing dynamic, adaptable solutions to new healthcare challenges. This partnership allows us to integrate cutting-edge technologies with revolutionary ideas.
ASSOCIATION WITH INNOVATIVE ENTITIES
ANPEI - To strengthen our dedication to innovation and collaborate with influential companies and institutions in stimulating national innovation, we do part of the National Association for Research and Development of Innovative Companies (ANPEI).
MIT-ILP - Reinforcing our commitment to excellence in innovation and with the firm purpose of bringing the best to Brazil, we are now members of the Massachusetts Institute of Technology (MIT), through the MIT Industrial Liaison Program (ILP).